The AHA appreciates the Medicare Payment Advisory Commission’s concerns about rising pharmaceutical costs and urged the Commission to continue to take action to achieve sustainable drug pricing. “Hospitals, and the clinicians who work in them, know firsthand the lifesaving potential of drug therapies … however, an unaffordable drug is not a lifesaving drug,” AHA said in a letter to MedPAC commissioners. AHA shared recommendations with MedPAC, including mandating an average sales price inflation cap for Medicare Part B and Part D drugs, and applying the cap to both high-cost and lower-cost drugs; identifying approaches to preventing excessively high launch prices as a response to an ASP inflation cap; maintaining the ASP plus 6 percent payment methodology for Part B drugs; testing a new Part D payment model that reduces or eliminates reinsurance payments while making appropriate adjustments to the direct subsidy rate; and improving annual public reports on Medicare Part B and Part D drug costs by making them more consumer and provider-friendly.

Related News Articles

Headline
The AHA expressed support Sept. 22 to House and Senate sponsors of the Medicare Advantage Prompt Pay Act (H.R. 5454/S. 2879), legislation that would apply a…
Headline
The Centers for Medicare & Medicaid Services Sept. 18 released a final rule on policy and technical changes to Medicare Advantage, the Medicare…
Headline
The Healthcare Association of New York State Sept. 16 announced Bea Grause, R.N., its president and CEO, will retire in summer 2026. Grause was active for many…
Headline
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
The AHA Sept. 15 urged Aetna to rescind its recently announced “level of severity inpatient payment” policy, saying that it “could erode the transparency…